News & Updates

Show Multimedia Only
Donanemab delays Alzheimer's disease progression over 3 years

Donanemab delays Alzheimer's disease progression over 3 years

04 Jun 2026 byKanas Chan

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026. 

04 Jun 2026